The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | T-Cell engaging treatment in AML
Marion Subklewe, MD, from the LMU-University Hospital, Munich, Germany, expresses how allogeneic stem cell transplantation is the mother of immunotherapy, which has proven the power of T-Cells. She summarises the topics in her talk, which focused on exploring alternative tools which are now evolving to recruit T-Cells for therapeutic strategies in acute myeloid leukemia (AML). Recently, a human, phase I multi-centre trial (NCT02520427) has been initiated which will administer AMG-330 for relapse-refractory AML, and a classical 3+3 design over the next 36 months to gather further data. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
